Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced Non-Small cell lung cancer following Platinum-Based doublet chemotherapy and immunotherapy (CANOPY-2): A Multicenter, Randomized, Double-Blind, phase 3 trial

Platinum-based doublet chemotherapy (PDC) and immune checkpoint inhibitor (ICI) therapy are standard of care for eligible patients with advanced non-small cell lung cancer (NSCLC) without targetable mutations [1]. Patients who progress on these therapies (either in combination or sequentially) have limited treatment options, which include single-agent chemotherapy, such as docetaxel, or combinations, such as docetaxel with the anti-angiogenic agents ramucirumab, nintedanib, or S-1 [1 –4]; however, these treatments provide only modest efficacy.

Source: Lung Cancer - January 15, 2024 Category: Cancer & Oncology Authors: Luis Paz-Ares, Yasushi Goto, Darren Wan-Teck Lim, Balazs Halmos, Byoung Chul Cho, Manuel Cobo, Jos é Luis González Larriba, Caicun Zhou, Ingel Demedts, Akin Atmaca, Sofia Baka, Bijoyesh Mookerjee, Socorro Portella, Zewen Zhu, Jincheng Wu, David Demanse, Source Type: research